Cargando…

Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database

BACKGROUND: This study examined demographics, comorbidities and healthcare resource use (HCRU) and costs among Japanese patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). METHODS: We conducted a repeated cross-sectional analysis of the Medical Data Vision...

Descripción completa

Detalles Bibliográficos
Autores principales: Terai, Shuji, Buchanan-Hughes, Amy, Ng, Alvin, Lee, I-Heng, Hasegawa, Ken
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7932941/
https://www.ncbi.nlm.nih.gov/pubmed/33496858
http://dx.doi.org/10.1007/s00535-021-01759-2
_version_ 1783660518483951616
author Terai, Shuji
Buchanan-Hughes, Amy
Ng, Alvin
Lee, I-Heng
Hasegawa, Ken
author_facet Terai, Shuji
Buchanan-Hughes, Amy
Ng, Alvin
Lee, I-Heng
Hasegawa, Ken
author_sort Terai, Shuji
collection PubMed
description BACKGROUND: This study examined demographics, comorbidities and healthcare resource use (HCRU) and costs among Japanese patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). METHODS: We conducted a repeated cross-sectional analysis of the Medical Data Vision (MDV) claims database, from January 2011 to March 2018. Demographics were described at index date and by calendar year; a “NASH” subpopulation included patients with ≥ 1 claim for NASH at any time. Prevalence of pre-specified comorbidities of interest and data-emergent top comorbidities were estimated. All-cause HCRU and costs were quantified by calendar year. Outcomes were compared between 2011 and 2017 using partially overlapping t tests. RESULTS: 58,958 patients (mean age 61.6 years; 55.5% male) were included. 1139 patients (2%) were in the NASH subpopulation. At baseline, comorbid cardiovascular disease (69.4%), diabetes (62.1%) and hyperlipidaemia (54.4%) were most prevalent; comorbidity prevalence increased with age. Mean outpatient visits decreased from 9.36 per patient in 2011 to 7.80 in 2017; mean inpatient admissions increased (both p < 0.001 for 2011 vs 2017). Mean total all-cause healthcare costs ranged from ¥322,206 to ¥340,399 per patient per year between 2011 and 2017. Although total all-cause healthcare costs did not change significantly (p = 0.552), cost burden shifted from the outpatient to inpatient setting between 2011 and 2017. All-cause healthcare resource use/costs were generally higher for the NASH subgroup compared with the overall population. CONCLUSIONS: There is a high burden of disease among Japanese NAFLD/NASH patients, including a high prevalence of comorbidities which generally increase with age. Accordingly, substantial all-cause HCRU and costs were incurred. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00535-021-01759-2.
format Online
Article
Text
id pubmed-7932941
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Singapore
record_format MEDLINE/PubMed
spelling pubmed-79329412021-03-19 Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database Terai, Shuji Buchanan-Hughes, Amy Ng, Alvin Lee, I-Heng Hasegawa, Ken J Gastroenterol Original Article—Liver, Pancreas, and Biliary Tract BACKGROUND: This study examined demographics, comorbidities and healthcare resource use (HCRU) and costs among Japanese patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). METHODS: We conducted a repeated cross-sectional analysis of the Medical Data Vision (MDV) claims database, from January 2011 to March 2018. Demographics were described at index date and by calendar year; a “NASH” subpopulation included patients with ≥ 1 claim for NASH at any time. Prevalence of pre-specified comorbidities of interest and data-emergent top comorbidities were estimated. All-cause HCRU and costs were quantified by calendar year. Outcomes were compared between 2011 and 2017 using partially overlapping t tests. RESULTS: 58,958 patients (mean age 61.6 years; 55.5% male) were included. 1139 patients (2%) were in the NASH subpopulation. At baseline, comorbid cardiovascular disease (69.4%), diabetes (62.1%) and hyperlipidaemia (54.4%) were most prevalent; comorbidity prevalence increased with age. Mean outpatient visits decreased from 9.36 per patient in 2011 to 7.80 in 2017; mean inpatient admissions increased (both p < 0.001 for 2011 vs 2017). Mean total all-cause healthcare costs ranged from ¥322,206 to ¥340,399 per patient per year between 2011 and 2017. Although total all-cause healthcare costs did not change significantly (p = 0.552), cost burden shifted from the outpatient to inpatient setting between 2011 and 2017. All-cause healthcare resource use/costs were generally higher for the NASH subgroup compared with the overall population. CONCLUSIONS: There is a high burden of disease among Japanese NAFLD/NASH patients, including a high prevalence of comorbidities which generally increase with age. Accordingly, substantial all-cause HCRU and costs were incurred. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00535-021-01759-2. Springer Singapore 2021-01-26 2021 /pmc/articles/PMC7932941/ /pubmed/33496858 http://dx.doi.org/10.1007/s00535-021-01759-2 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Article—Liver, Pancreas, and Biliary Tract
Terai, Shuji
Buchanan-Hughes, Amy
Ng, Alvin
Lee, I-Heng
Hasegawa, Ken
Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database
title Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database
title_full Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database
title_fullStr Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database
title_full_unstemmed Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database
title_short Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database
title_sort comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) in the japan medical data vision database
topic Original Article—Liver, Pancreas, and Biliary Tract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7932941/
https://www.ncbi.nlm.nih.gov/pubmed/33496858
http://dx.doi.org/10.1007/s00535-021-01759-2
work_keys_str_mv AT teraishuji comorbiditiesandhealthcarecostsandresourceuseofpatientswithnonalcoholicfattyliverdiseasenafldandnonalcoholicsteatohepatitisnashinthejapanmedicaldatavisiondatabase
AT buchananhughesamy comorbiditiesandhealthcarecostsandresourceuseofpatientswithnonalcoholicfattyliverdiseasenafldandnonalcoholicsteatohepatitisnashinthejapanmedicaldatavisiondatabase
AT ngalvin comorbiditiesandhealthcarecostsandresourceuseofpatientswithnonalcoholicfattyliverdiseasenafldandnonalcoholicsteatohepatitisnashinthejapanmedicaldatavisiondatabase
AT leeiheng comorbiditiesandhealthcarecostsandresourceuseofpatientswithnonalcoholicfattyliverdiseasenafldandnonalcoholicsteatohepatitisnashinthejapanmedicaldatavisiondatabase
AT hasegawaken comorbiditiesandhealthcarecostsandresourceuseofpatientswithnonalcoholicfattyliverdiseasenafldandnonalcoholicsteatohepatitisnashinthejapanmedicaldatavisiondatabase